Americans now have an additional treatment option for managing high cholesterol: a once-a-day oral medication. Elevated levels of LDL cholesterol, commonly known as “bad” cholesterol, build up in the arteries, thereby increasing the risk of cardiovascular events such as heart attacks, strokes, and various vascular diseases. The new drug is positioned as a potential alternative or adjunct to statins.
While statins are established, effective, and generally safe medications, individual patient tolerance varies, and in some cases, the maximum tolerated dosage may not achieve sufficient cholesterol reduction to reach a consistently safe level. The medication, referred to as “Lipfrena,” is a PCSK9 inhibitor. Its prescribing information suggests it can be administered either alongside or instead of a statin regimen.
The drug is intended to help lower LDL cholesterol levels and can be utilized as an added measure when combined with lifestyle modifications, including dietary changes. This development offers patients more flexibility in managing their cardiovascular risk factors. The introduction of this medication expands the therapeutic options available to healthcare providers and patients managing dyslipidemia.
Topics: #cholesterol #new #safe
